%20(2)_edited.png)
Welcome to Concilium Investors
Concilium is in the advanced stages of launching our platform.
The first physicians are already using our system—sharing feedback, helping us sharpen the product, and most importantly, taking part in the ambitious vision we’ve built.
After six intense months of work, we’re entering our go-to-market phase.
​
And this is where you come in:
Concilium is opening its first investment round - a Friends & Family round designed to propel us into the next stage of growth.
Our core goal is to reach break-even within the first eight months, and become a profitable company within our first year.
Here you’ll find the full details: our roadmap, what’s next, and what you can gain by joining early.
We’re inviting you to step into an adventure that carries real risk—and at the same time has the potential to fundamentally reshape the global medical aesthetics market.
Executive Summery:
We’re raising $120,000 for 10% of the company in a Friends & Family round.
After six months of intensive work - and with our product now launching - we’re opening this round to take us through the next phase: reaching break-even within an additional six months, and moving from there to profitability
The product:​
An AI platform that performs deep assessment and provides real-time guidance for physicians injecting botulinum toxin and hyaluronic acid.
Target audience:
Phase one: physicians in their first two years in medical aesthetics.
Phase two: physicians in their first five years in medical aesthetics.
Investment package:
$24,000
Total offering:
5 packages available (up to 10% of the company)
The market problem:
Medical aesthetics suffers from a severe lack of consolidated, standardized professional knowledge.
Many doctors enter the field with little to no structured training, leading to fear, low confidence, and professional mistakes that impact both clinicians and patients. Around 80% of physicians who enter the field leave within two years.
Equity per package:
- 2% Of the company
Estimated time to return on investment:
30 months (2.5 years).
Get Ready For Deep Dive:
.png)
About Concilium
Concilium is an AI-powered technology platform that guides and supports physicians in medical aesthetics in real time.
It accompanies the doctor from the diagnostic stage, through the automatic creation of a treatment plan, all the way to precise guidance for each and every injection.
Our core differentiation lies in the extensive knowledge base we’ve built-grounded in expertise accumulated by leading professors and senior physicians across tens of thousands of injection hours.
In phase one, the system is designed to support new physicians entering the field-young doctors and those making a professional transition-and to accompany them through their first two years, when close guidance and mentorship are critically needed.
These are the two years in which, according to research, around 80% of physicians who enter the field end up leaving it due to the severe lack of training and hands-on mentorship that would give them confidence.
In phase two, according to our roadmap, both the platform and the knowledge base will expand to deliver professional depth and advanced insights for more experienced physicians as well. This stage will follow once we establish our position during the first year as a knowledge-driven, AI-powered digital mentor for early-career doctors.
The Market’s core problems
The market’s biggest pain points stem from a severe lack of structured, high-quality training - both theoretical and hands-on - in medical aesthetics.
New physicians consistently report major fears and uncertainties during their first two years in the field: low confidence due to limited training and mentorship, a shortage of reliable, expert-approved knowledge, and the absence of a clear methodology they can learn from sources they truly trust.​​​
For a deeper dive into these market problems, we’ve attached a strategic summary report with research references, along with an AI-powered podcast that reviews in-depth studies in the field:
01
Extremely high dropout rates (around 80%, according to research) - Lack of mentorship drives early exits and burnout.
02
Fear and shaky hands: High-stakes injections without real-time, expert guidance
03
Low confidence in front of patients: Unclear planning makes consultations feel fragile.
04
Difficulty understanding patient’s real needs: No structured diagnostic framework or decision support.
05
Difficulty meeting patient expectations: Inconsistent outcomes without standardized treatment planning.
06
Relying on different sources for every treatment: leading to practical and emotional confusion - Fragmented learning creates uncertainty, mixed protocols, and doubt.
.png)
Our Unique Knowledge Base
Concilium’s biggest advantage is the extensive knowledge base we’ve built.
For the first time, so much accumulated expertise from professors and senior physicians has been consolidated into a single, validated source.
It’s a rare blend of verified clinical authority and massive real-world experience. Tens of thousands of injection hours are embedded into the content - translating real clinic-level know-how into clear, structured protocols. This allows us to deal with true anatomical variability and edge cases, not just idealized textbook scenarios.​
​
Our Knowledge base also creates standardization: a shared language and a consistent methodology - essentially a Clinical Operating System for medical aesthetics. Our knowledge base is difficult to replicate, both because of the expert validation process and the depth of accumulated experience behind it. And as the platform engages with more physicians and more real-world cases, the knowledge base keeps evolving - becoming sharper and more precise over time.
Business Plan
Our business plan is built around the resources and experience available to Concilium’s founding team.
​
In our first year, we’ll focus on the Israeli market to establish the platform, the brand, and our ability to become financially self-sustaining. We’re leveraging Professor Eyal Winkler’s extensive network, the clinic brand led by Assaf Winkler, and the strategic leadership of Arad Akikous - along with our ability to reach virtually any physician, academic institution, or key stakeholder in the Israeli market with relative ease. Our goal is to reach break-even within the first six months and continue growing in line with our business targets.
​​
Under a reasonable scenario, we do not expect to require additional funding beyond the current round in order to operate the company for years, and to expand into additional target markets.​
.png)
In the second year, we’ll expand into new markets through partnerships with local distributors, as is standard in the medical aesthetics industry. According to the plan, entering each target country will be done via revenue-sharing partnerships, without the need to build heavy local infrastructure.
​​
There is also a scenario in which we may choose to raise additional capital for aggressive marketing and for developing advanced technologies. It’s important to note that, at this stage, such rounds are considered a contingency plan rather than part of the company’s concrete near-term plan.
Target Audience
We’ll execute our initial market entry in Israel, where our ability to reach physicians is strongest and our pilot market is most efficient.
Globally, we’ll work with local distributors whose role is to connect us with physicians in each country in exchange for a percentage of sales.
As mentioned, in phase one we’ll focus on early-career doctors in their first two years of practice. In phase two, as the platform evolves, we’ll also deliver meaningful value to more experienced physicians.
The Investment
In the current Friends & Family round, we’re raising $120,000 in exchange for 10% of the company, with each investor able to invest up to 3%.
We’re looking to partner with 3–5 investors to spread risk and create strategic alignment with experienced business leaders who will walk with us on the path to building Concilium into a successful company.
.png)
Total investment required:
$120,000
Divided into investment tranches with a minimum of $12,000 each
Total equity offered:
10%
Allocated at 1% per $12,000 invested.